ArticleFrontiers in surgery2025
Microvascular decompression for neurovascular compression syndromes secondary to vertebrobasilar dolichoectasia: a single-center retrospective analysis.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vertebrobasilar dolichoectasia (VBD) is a rare cause of neurovascular compression syndromes (NVCS), including trigeminal neuralgia (TN), hemifacial spasm (HFS), and glossopharyngeal neuralgia (GPN). Microvascular decompression (MVD) is the primary surgical treatment; however, VBD-related cases are technically challenging and carry a higher risk of complications. Objective: To analyze the clinical characteristics, surgical findings, outcomes, and complications of patients with NVCS secondary to VBD treated with MVD. Methods: A retrospective single-center study was conducted on 68 patients who underwent MVD for VBD-associated NVCS between January 2014 and December 2024. Clinical, imaging, intraoperative, and postoperative data were collected and analyzed. Interposition and transposition techniques were employed according to intraoperative findings. Results: Among the 68 patients, TN was present in 49 cases (72.1%), HFS in 7 (10.3%), GPN in 4 (5.9%), and combined neuropathies in 8 (11.8%). Complete symptom relief was achieved in 92.5% of TN/GPN cases and 55.6% of HFS. During follow-up (mean = 27.3 months), TN recurred in 5.3% and HFS in 11.1%. Transient complications occurred in 67.6%, of patients, while persistent deficits were reported in 36.8%. Comparative analysis showed that patients with VBD were older ( Conclusions: MVD remains a safe and effective treatment for NVCS caused by VBD. However, the technical complexity of these cases demands meticulous surgical planning and long-term follow-up. Both interposition and transposition techniques yielded favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.